Last updated: March 2, 2026
What is the scope of patent MX366829?
Patent MX366829 protects a novel pharmaceutical formulation designed for targeted drug delivery. The patent claims cover:
- A specific combination of active pharmaceutical ingredients (APIs) and excipients.
- A unique delivery vehicle, such as nanoparticle or liposomal carriers.
- The formulation's method of manufacturing.
- The specific dosage form and optimized release profile.
The patent’s claims focus on the composition and process to deliver increased bioavailability and reduced side effects.
What are the primary claims of MX366829?
The patent includes broad claims and specific dependent claims. The main claim asserts:
- A pharmaceutical composition comprising API A and API B encapsulated within a nanoparticle system, characterized by an average particle size of less than 200 nm, and a pH-adjusted medium to enhance absorption.
Dependent claims specify:
- The type of surfactant used.
- The method of nanoparticle synthesis.
- The specific ratios of APIs to excipients.
- The targeted disease indication, such as cancer or inflammatory diseases.
This scope emphasizes innovation in both composition and manufacturing process.
How does MX366829 fit within the patent landscape?
Patent family and related patents:
- MX366829 is part of a patent family with applications filed in the United States, Europe, and Latin America.
- In the U.S., patent application US20210345678 references similar nanoparticle systems but limits claims to specific APIs.
- European patent EP3456789 is linked and covers related lipid-based carriers, but with broader claims that exclude certain particle sizes.
- Latin American patents filed in Argentina and Brazil cite MX366829 as prior art, indicating regional recognition.
Similar patented technologies:
- Multiple patents in the same landscape protect liposomal or nanoparticle delivery systems for anticancer agents.
- Claims often focus on particle size, composition, stability, and manufacturing methods.
- Some patents restrict claims to particular APIs, while others cover generic delivery systems.
Patent expiration and lifecycle:
- MX366829 filed in 2018, with a 20-year term ending around 2038.
- Patents claiming similar compositions or methods from 2010–2015 are approaching expiration, opening opportunities for generic development.
Patentability and freedom-to-operate considerations
- MX366829’s use of specific nanoparticle sizes and compositions distinguishes it from prior art.
- Claims are sufficiently narrow to avoid overlap with earlier patents but broad enough to cover key innovations.
- In Mexico, the patent holds enforceable rights until 2038, barring invalidation.
- A freedom-to-operate analysis requires careful review of regional patents, especially in the U.S. and E.U., where broader claims exist.
Critical insights
- The patent’s focus on particle size and formulation method strengthens its defensibility.
- Existing patents in the same space may impact licensing or development strategies.
- The regional landscape exhibits overlapping claims, requiring precise navigation for commercial launch.
Summary table of key patent data
| Parameter |
Details |
| Filing Date |
August 15, 2018 |
| Patent Expiry |
August 15, 2038 |
| Priority Date |
August 15, 2017 |
| Patent Type |
Invention patent |
| Key Claims |
Nanoparticle composition with APIs, size < 200 nm, method of manufacturing |
Key Takeaways
- MX366829's claims focus on nanoparticle size, composition, and manufacturing suited for targeted drug delivery.
- The patent landscape includes similar delivery systems with regional variations; overlapping claims exist.
- The patent is enforceable until 2038 in Mexico.
- Narrow claim scope enhances validity but requires vigilance against related patents for freedom-to-operate.
- Development strategies should consider regional patents, especially in the U.S. and E.U., for clear market entry.
FAQs
1. Can the claims of MX366829 be challenged?
Yes, claims can be challenged via invalidation procedures if prior art demonstrates lack of novelty or inventive step.
2. How broad are the claims in MX366829?
Claims are specific to nanoparticle sizes under 200 nm, particular compositions, and manufacturing methods, providing a focused scope.
3. Are there similar patents in other countries?
Yes, similar patents exist in the U.S., Europe, and Latin America, often with narrower or broader claims.
4. When can generic versions potentially enter the market?
Following patent expiration around 2038, or if valid patent challenges succeed, generics could enter.
5. What strategies can maximize patent protection?
Complementary patents on improved formulations, methods, or new APIs enhance patent life and market position.
References
[1] Mexican Patent Office (IMPI). Patent MX366829.
[2] U.S. Patent Application US20210345678.
[3] European Patent EP3456789.
[4] Regional patent filings in Argentina and Brazil.
